| Schedule of segment operating loss and asset information |
| Schedule of segment operating loss and
asset information | |
| | | |
| | |
| Schedule of segment operating loss and asset information as of June 30, 2026 | |
| |
|
| | |
Operating loss | |
Assets |
| United States (RENB) | |
$ | 7,228,528 | | |
$ | 3,699,015 | |
| Canada (BioSymetrics) | |
| 1,123,698 | | |
| 6,242,773 | |
| Netherlands (RENC) | |
| 345,707 | (1) | |
| — | |
| | |
$ | 8,697,933 | | |
$ | 9,941,788 | |
(1) Amount represents operating expenses incurred during the year ended June 30, 2026, prior to the subsidiary's bankruptcy on September 2, 2025. No additional operating expenses were incurred by the subsidiary following the bankruptcy.
| Schedule of segment operating loss and asset information as of June 30, 2025 | |
| |
|
| | |
Operating loss | |
Assets |
| United States (RENB) | |
$ | 15,530,056 | | |
$ | 1,907,647 | |
| Canada (BioSymetrics) | |
| 237,880 | | |
| 6,109,643 | |
| Netherlands (RENC) | |
| 173,198,066 | | |
| 213,550 | |
| | |
$ | 188,966,002 | | |
$ | 8,230,840 | |
|
| Schedule of information regarding segment reporting |
| Schedule of information regarding segment reporting | |
| | | |
| | | |
| | | |
| | |
| | |
RENB | |
BioSymetrics | |
RENC | |
Total |
| Service Revenue | |
$ | — | | |
$ | 51,992 | | |
$ | — | | |
$ | 51,992 | |
| General and administrative | |
| 6,278,062 | | |
| 1,176,201 | | |
| 345,707 | | |
| 7,799,970 | |
| Research and development | |
| 67,185 | | |
| (42,667 | ) | |
| — | | |
| 24,518 | |
| Long-lived asset impairment | |
| 831,915 | | |
| — | | |
| — | | |
| 831,915 | |
| Depreciation and amortization | |
| 51,366 | | |
| 42,156 | | |
| — | | |
| 93,522 | |
| | |
| | | |
| | | |
| | | |
| | |
| Segment operating loss | |
$ | 7,228,528 | | |
$ | 1,123,698 | | |
$ | 345,707 | | |
| 8,697,933 | |
Information
regarding each reportable segment for the year ended June 30, 2025 is as follows:
| | |
| | | |
| | | |
| | | |
| | |
| | |
RENB | |
BioSymetrics | |
RENC | |
Total |
| General and administrative | |
$ | 14,904,855 | | |
$ | 211,401 | | |
$ | 2,763,794 | | |
$ | 17,880,050 | |
| Research and development | |
| 502,896 | | |
| 26,029 | | |
| 8,503 | | |
| 537,428 | |
| Goodwill impairment | |
| — | | |
| — | | |
| 170,419,429 | | |
| 170,419,429 | |
| Depreciation and amortization | |
| 122,305 | | |
| 450 | | |
| 6,340 | | |
| 129,095 | |
| | |
| | | |
| | | |
| | | |
| | |
| Segment operating loss | |
$ | 15,530,056 | | |
$ | 237,880 | | |
$ | 173,198,066 | | |
| 188,966,002 | |
|